09 – A New Era of GVHD Prevention Post-HCT, Pt. 1: PTCy and Improved Outcomes

In this two-part episode, Javier Bolaños-Meade, MD, with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Shernan Holtan, MD, with the University of Minnesota discuss advances and innovations in graft-versus-host disease (GVHD) prevention that call for a new standard of care in patients needing allogeneic hematopoietic cell transplantation.

In Part I: PTCy and Improved Outcomes, experts highlight the history of GVHD prevention and the impacts of post-transplant cyclophosphamide (PTCy) in particular in improving outcomes and closing gaps in access to care.

To read bios on the panelists and to access additional resources related to this episode, visit Our Site.